New hope for rare cancer: drug cocktail targets stubborn LCH
NCT ID NCT07204041
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial tests a combination of three drugs—selinexor, thalidomide, and dexamethasone—in 40 adults with relapsed or refractory Langerhans cell histiocytosis (LCH), a rare immune cell disorder. The goal is to see if the XTD regimen can shrink tumors and delay disease progression. Participants take the drugs orally in 28-day cycles for up to 12 cycles.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Selinexor, thalidomide, and dexamethasone (XTD regimen)
- What this could lead to
- If successful, this could offer a new treatment option for adults with hard-to-treat Langerhans cell histiocytosis, potentially controlling the disease and improving survival.
- What could go wrong
- This is a small, early-phase trial with no comparison group, so results may not apply broadly. The drugs have known side effects like fatigue, blood clots, and nerve damage.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LANGERHANS CELL HISTIOCYTOSIS (LCH) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, beijing,
Beijing, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could existing cancer drugs tackle rare tumors? new trial aims to find out
- New targeted drug combo aims to curb relapse in kids with rare immune disorder
- Scientists hunt for genetic clues in rare blood disorders
- New pill could spare kids with rare bone disease from chemo
- Old drug, new hope: lenalidomide tackles rare histiocyte cancers
- New pill shows promise for rare childhood diseases